Shares of NewLink Genetics Corp (NASDAQ:NLNK) traded down 10.5% on Tuesday . The stock traded as low as $3.75 and last traded at $4.56. 829,134 shares were traded during mid-day trading, a decline of 26% from the average session volume of 1,121,385 shares. The stock had previously closed at $4.13.
Several analysts have recently weighed in on the company. Cantor Fitzgerald set a $7.00 price objective on NewLink Genetics and gave the company a “hold” rating in a report on Monday. Robert W. Baird lowered NewLink Genetics from an “outperform” rating to a “neutral” rating and cut their price objective for the company from $22.00 to $5.00 in a report on Monday, April 9th. Jefferies Group restated a “hold” rating on shares of NewLink Genetics in a report on Thursday, April 12th. Bank of America lowered NewLink Genetics from a “buy” rating to a “neutral” rating in a report on Friday, April 6th. Finally, Zacks Investment Research lowered NewLink Genetics from a “buy” rating to a “hold” rating in a report on Thursday, January 4th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and one has issued a buy rating to the company. NewLink Genetics presently has a consensus rating of “Hold” and an average target price of $12.86.
The firm has a market cap of $153.27, a P/E ratio of -1.97 and a beta of 1.22.
NewLink Genetics (NASDAQ:NLNK) last announced its earnings results on Thursday, March 1st. The biotechnology company reported ($0.37) EPS for the quarter, beating the consensus estimate of ($0.69) by $0.32. NewLink Genetics had a negative return on equity of 60.60% and a negative net margin of 250.60%. The business had revenue of $10.10 million during the quarter, compared to the consensus estimate of $2.72 million. equities research analysts anticipate that NewLink Genetics Corp will post -2.32 EPS for the current fiscal year.
Several hedge funds and other institutional investors have recently made changes to their positions in NLNK. State Street Corp lifted its holdings in shares of NewLink Genetics by 1.2% during the second quarter. State Street Corp now owns 391,464 shares of the biotechnology company’s stock valued at $2,875,000 after purchasing an additional 4,630 shares during the last quarter. The Manufacturers Life Insurance Company lifted its holdings in shares of NewLink Genetics by 3.0% during the second quarter. The Manufacturers Life Insurance Company now owns 19,069 shares of the biotechnology company’s stock valued at $140,000 after purchasing an additional 556 shares during the last quarter. Ameriprise Financial Inc. lifted its holdings in shares of NewLink Genetics by 207.1% during the third quarter. Ameriprise Financial Inc. now owns 311,927 shares of the biotechnology company’s stock valued at $3,176,000 after purchasing an additional 210,360 shares during the last quarter. Stifel Financial Corp purchased a new stake in shares of NewLink Genetics during the third quarter valued at $402,000. Finally, Point72 Asset Management L.P. purchased a new stake in shares of NewLink Genetics during the third quarter valued at $1,819,000. 65.05% of the stock is owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION WARNING: “NewLink Genetics (NLNK) Trading Down 10.5%” was originally published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this story on another site, it was stolen and reposted in violation of US and international copyright & trademark law. The legal version of this story can be accessed at https://ledgergazette.com/2018/04/19/newlink-genetics-nlnk-trading-down-10-5.html.
About NewLink Genetics
NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.
Receive News & Ratings for NewLink Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics and related companies with MarketBeat.com's FREE daily email newsletter.